Hypertension, commonly known as high blood pressure, is a medical condition characterized by elevated force of blood against the walls of arteries. coronary artery disease also known as coronary artery disease, results from the gradual accumulation of fatty deposits (atherosclerosis) in the coronary arteries, which supply oxygen and nutrients to the heart muscle.
Stroke is intimately connected to the increasing prevalence of hypertension and Coronary Heart Disease (CHD) patients due to shared risk factors and underlying physiological mechanisms. Hypertension, or high blood pressure, significantly raises the risk of stroke by damaging blood vessels and increasing the likelihood of blood clots. Prolonged hypertension can lead to atherosclerosis and accumulation of fatty deposits in arteries. This can result in narrowed blood vessels and reduced blood flow to the brain, increasing the risk of both ischemic (caused by blockages) and hemorrhagic (caused by bleeding) strokes. High blood pressure can also damage the blood vessels in the brain, making them more prone to rupture or blockage, further escalating the stroke risk.
Coronary heart disease, characterized by plaque build-up in the coronary arteries, is closely related to stroke through several pathways. atherosclerosis, common in both coronary heart disease and stroke, can affect arteries throughout the body. When it occurs in the arteries supplying blood to the brain, it can cause blockages or plaque ruptures that lead to stroke. Moreover, coronary heart disease can lead to the formation of blood clots, which, if dislodged, can travel to the brain and block smaller blood vessels, causing ischemic strokes.
These conditions also share many risk factors, such as obesity, diabetes, high cholesterol, and a sedentary lifestyle, which can increase the likelihood of both hypertension and coronary heart disease and, consequently raise the risk of stroke.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-stroke-market
Data Bridge Market Research analyses that the Stroke Market is expected to grow with a CAGR of 7.5% in the forecast period from 2023 to 2030, and is expected to reach USD 52,232,195.85 thousand by 2030. In 2023, the ischemic stroke segment is expected to dominate the market due is rising incidences of stroke.
Key Findings of the Study
Expansion of Telemedicine and Remote Monitoring
The expansion of telemedicine and remote monitoring has been a significant development in stroke treatment and care. These technologies offer numerous advantages, including increased accessibility, rapid assessment, and continuous monitoring, which can significantly improve stroke patients' management and outcomes.
Telemedicine enables patients to have real-time video consultations with healthcare providers, particularly stroke specialists. In the event of a stroke, time is of the essence, and telemedicine allows for immediate assessment and decision-making, reducing delays in treatment. Telemedicine also extends stroke care to underserved and rural areas, where access to stroke specialists may be limited. Patients in remote locations can contact experts for rapid evaluation and treatment recommendations. In addition, telemedicine helps establish stroke networks, connecting primary care hospitals and community clinics with comprehensive stroke centers and these networks allow for expert consultations and efficient patient transfer when necessary. Moreover, telemedicine can aid in determining the eligibility of a patient for thrombolytic therapy, which involves clot-busting drugs. Specialists can assess CT scans remotely, ensuring eligible patients receive this time-sensitive treatment promptly.
Further remote monitoring after stroke can track patients' vital signs, medication adherence, and recovery progress from their homes. This allows healthcare providers to monitor patients continuously, detect issues early, and adjust treatment plans. Stroke survivors can benefit from telerehabilitation programs, where they receive therapy and exercises guided by remote therapists via video calls. This increases access to crucial rehabilitation services, particularly for those with mobility limitations. Remote monitoring can assist with medication management. Smart pill dispensers and wearable devices can remind patients to take their medications and monitor whether they have done so. This helps prevent secondary strokes by ensuring proper medication adherence.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Thousand
|
|
Segments Covered
|
Type (Ischemic Stroke, Transient Ischemic Attack (TIA) and Hemorrhage Stroke), Treatment (Medication, Surgery, and Other Therapy), Diagnosis (Imaging Test, Blood Test, Echocardiogram, Lumbar Puncture, and Other), Gender (Female and Male), End User (Hospitals & Clinics, Specilaty Clinics, Ambulatory Surgical Centers, Homecare, Laboratories and Others), Distribution Channel (Direct, Retail and Online)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, U.K., France, Russia, Italy, Spain, Turkey, Poland, Belgium, Netherlands, Switzerland, Denmark, Sweden, Norway, Finland, Rest of Europe, China, Japan, India, Australia, South Korea, New Zealand, Singapore, Thailand, Philippines, Malaysia, Indonesia, Vietnam, Taiwan, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Qatar, Kuwait, Oman, Bahrain and Rest of Middle East and Africa
|
|
Market Players Covered
|
Bayer AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Boehringer Ingelheim International GmbH (Germany), Sanofi (France), Bristol-Myers Squibb Company (U.S.), Johnson & Johnson Services, Inc. (U.S.), Medtronic (Ireland), Teva Pharmaceuticals USA, Inc. (Israel), Pfizer Inc. (U.S.), AstraZeneca (U.K.), Viatris Inc. (U.S), Lupin (India), Abbott (U.S.), DAIICHI SANKYO COMPANY, LIMITED (Japan), Penumbra, Inc. (U.S.), Oxford Laboratories Pvt. Ltd. (India), Sandoz Group AG (Subsidiary of Novartis AG) (Switzerland), GLENMARK PHARMACEUTICALS LTD. (India), Fresenius SE & Co. KGaA (Germany), and Amneal Pharmaceuticals LLC (U.S.), among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis
The global stroke market is categorized into six notable segments based on type, treatment, diagnosis, gender, end user, and distribution channel.
- On the basis of type, the market is segmented into ischemic stroke, hemorrhagic stroke, and Transient Ischemic Attack (TIA).
In 2023, the ischemic stroke segment is expected to dominate the global stroke market
In 2023, the ischemic stroke segment is expected to dominate the market with 76.78% market share due to rising incidences of stroke.
- On the basis of treatment, the market is segmented into medication, surgery, and other therapy.
In 2023, the medication segment is expected to dominate the global stroke market
In 2023, the medication segment is expected to dominate the market with 82.66% market share due to advancements in medical technology for stroke treatment.
- On the basis of diagnosis, the market is segmented into imaging test, blood test, echocardiogram, lumbar puncture, and others. In 2023, the imaging test segment is expected to dominate the market with 67.21% market share.
- On the basis of gender, the market is segmented into female and male. In 2023, the female segment is expected to dominate the market with 56.17% market share.
- On the basis of end-user, the market is segmented into hospitals & clinics, specialty clinics, ambulatory surgical center, homecare, laboratories, and others. In 2023, the hospitals & clinics segment is expected to dominate the market with 52.94% market share.
- On the basis of distribution channel, the market is segmented into direct, retail, and online. In 2023, the direct tenders segment is expected to dominate the market with 78.35% market share.
Major Players
Data Bridge Market Research analyzes Bristol-Myers Squibb Company (U.S.), Boehringer Ingelheim International GmbH. (Germany), F. Hoffmann-La Roche Ltd (Switzerland), DAIICHI SANKYO COMPANY, LIMITED. (Japan), Sanofi (France) as the major players of the market.
Market Development
- In May 2023, Bristol Myers Squibb (NYSE: BMY) in partnership with Janssen Pharmaceuticals, Inc., one of the Janssen pharmaceutical companies of Johnson & Johnson (Janssen), announced that all three potential indications for milvexian, an investigational oral factor XIa (FXIa) inhibitorhas now received fast track designation from the U.S. Food and Drug Administration (FDA). The names include all three trials seeking indications in the Phase 3 Librexiadevelopment program (Librexia STROKE, Librexia ACS, and Librexia AF), all dosed patients. The Librexia program is unparalleled as a comprehensive clinical development program for FXIa, providing extensive data from nearly 50,000 patients. This opens the door to a whole new range of currently neglected patients due to the risk of bleeding.
- In January 2023, Penumbra, Inc., a global healthcare company focused on innovative therapies, announced the U.S. Food and Drug Administration (FDA) approval and launch of Lightning Flash, the most advanced and powerful mechanical thrombectomy system on the market. Lightning Flash features Penumbra's new Lightning Intelligent Aspiration technology, which now has two clot detection algorithms. Combined with innovative catheter technology, the Lightning Flash is designed to quickly remove large blood clots from the body, including venous embolism and pulmonary embolism (PE). This launch will help the company expand its product portfolio because the advanced results of this new technology are exceptionally traceable, and it has the unique ability to differentiate flowing blood from clots.
- In July 2023, Roche announced a new partnership with Alnylam to develop and commercialize zilebesir, an investigational RNAi therapy currently in Phase 2 for treating high blood pressure. This collaboration combines Alnylam's proven experience in RNAi therapy with Roche's global commercial reach, commitment to innovation, and desire to change the landscape for patients with severe cardiovascular disease.
- In February 2021, Sanofi’s Plavix (clopidogrel) got approval by the European Commission for its use in combination with aspirin in adult patients with moderate or high-risk transient ischemic attack (TIA) (ABCD2 score ≥4) or mild ischemic stroke (IS). Twenty-four hours of a TIA or IS event. In this new indication, use can be continued for 21 days, followed by long-term single antiplatelet therapy. The additional indication is based on the results of a two-investigator-initiated, double-blind, randomized, placebo-controlled phase 3 study involving more than 10,000 patients. Studies have shown that the combination of clopidogrel and aspirin started within 24 hours is better than aspirin in reducing the risk of subsequent stroke and has a generally acceptable safety profile. This new approval demonstrates companies unwavering commitment to advancing cardiovascular care.
- In September 2020, Daiichi Sankyo Company Limited announced that it had submitted a supplemental application in Japan for the extended approval of the anticoagulant edoxaban (edoxaban benzoate hydrate) in elderly patients with nonvalvular regurgitation and severe bleeding risk. This application is based on the results of a Japanese Phase 3 clinical trial (ELDERCARE-AF trial) in 984 patients with non-valvular atrial fibrillation who are at least 80 years old and have a high risk of bleeding and are not suitable for other available anticoagulant therapies. Daiichi Sankyo plans to contribute to treating elderly patients with non-valvular atrial fibrillation by offering a new treatment option.
Regional Analysis
Geographically, the countries covered in the global Stroke Market report are the U.S., Canada, Mexico, Germany, U.K., France, Russia, Italy, Spain, Turkey, Poland, Belgium, Netherlands, Switzerland, Denmark, Sweden, Norway, Finland, Rest of Europe, China, Japan, India, Australia, South Korea, New Zealand, Singapore, Thailand, Philippines, Malaysia, Indonesia, Vietnam, Taiwan, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Qatar, Kuwait, Oman, Bahrain and Rest of Middle East and Africa.
As per Data Bridge Market Research analysis:
North America is expected to dominate the global stroke market
North America is expected to dominate the market owing to the high demand for stroke in the region and the rise in healthcare expenditure. North America will continue to dominate the stroke market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period.
Asia-Pacific is estimated to be the fastest-growing region in global stroke market
Asia-Pacific is estimated to be the fastest-growing region in the market for the forecast period 2023 -2030. This is due to the growing adoption of advanced technology and the launch of new products in this region.
For more detailed information about the global stroke market report, click here – https://www.databridgemarketresearch.com/reports/global-stroke-market
